Abstract: This disclosure relates to methods administering hydroxybupropion or a prodrug thereof in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and hydroxybupropion or a prodrug of hydroxybupropion are also disclosed.
Abstract: Compositions and methods for the treatment of depression and psychoses in humans are disclosed. More particularly, the invention is directed to formulations containing antipsychotic and/or antidepressant medications and also containing an NMDAR antagonist. The present Invention Is also directed to methods tor the treatment of humans suffering from depression and other psychoses, including, schizophrenia, by administration of the inventive compositions in antidepressant and/or antipsychotic effective amounts.
Abstract: Use of sparstolonin B in inhibition of growth and/or viability of human neuroblastoma cells is described. The sparstolonin B can be naturally derived from the Chinese herb Sparganium stoloniferum or can be synthetic. The sparstolonin B is shown to be effective both in vitro and in vivo in inhibition of growth and/or viability of neuroblastoma cells of multiple different genetic backgrounds including N-myc amplified with wild p53 neuroblastoma cells, N-myc amplified with mutated p53 neuroblastoma cells, and N-myc nonamplified neuroblastoma cells.
Type:
Grant
Filed:
September 11, 2014
Date of Patent:
September 20, 2016
Assignee:
University of South Carolina
Inventors:
Ambrish Kumar, Ugra Sen Singh, Daping Fan, Donald J. Dipette
Abstract: The present invention relates to treating a hematologic cancer using a Hypoxia-Inducible Factor (HIF inhibitor). The invention also relates to inducing acute myeloid leukemia remission using the HIF inhibitor. The invention further relates to inhibiting a maintenance or survival function of a cancer stem cell (CSC) using the HIF inhibitor.
Type:
Grant
Filed:
June 25, 2010
Date of Patent:
August 30, 2016
Assignee:
OncoImmune, Inc.
Inventors:
Yang Liu, Yin Wang, Yan Liu, Sami N. Malek, Pan Zheng
Abstract: The present invention relates to a biodegradable injectable composition for bone augmentation comprising fibrin, a contrast agent and calcium salt-containing particles, as well as a method for bone augmentation in a patient suffering from a bone disorder comprising injecting said composition into a non-mineralized or hollow portion of said bone.
Type:
Grant
Filed:
April 17, 2007
Date of Patent:
August 23, 2016
Assignees:
Baxter International Inc., Baxter Healthcare S.A.
Inventors:
John J. Barry, Andreas Goessl, Heinz Gulle, Monika Mangold, Melitta Bilban
Abstract: In the present invention, a method using a combination of iguratimod or a salt thereof and one or more immunosuppressants is useful as a method for the treatment of autoimmune diseases, and with this method adverse effects are lessened. A pharmaceutical composition containing this combination is useful for the treatment of autoimmune diseases. This method and pharmaceutical composition are useful for the treatment of more severe autoimmune diseases.
Abstract: The present invention relates to a method and compositions for the treatment of cystic fibrosis.
Type:
Grant
Filed:
August 13, 2013
Date of Patent:
August 2, 2016
Assignees:
INSERM (Institut National de la Sante et de la Recherche Medicale), Universite Paris-Est Creteil Val de Marne, Assistance Publique-Hopitaux de Paris
Abstract: The present invention relates to low dose estradiol solutions for oromucosal administration suitable in replacement therapy or suppletion of low estradiol levels and also for preventing, alleviating or treating symptoms associated with low endogenous levels of estradiol in female subjects.
Type:
Grant
Filed:
January 4, 2013
Date of Patent:
August 2, 2016
Assignee:
INNOTESTO BVBA
Inventor:
Franciscus Wilhelmus Henricus Maria Merkus
Abstract: This disclosure relates to methods administering threohydroxybupropion or a prodrug thereof in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and threohydroxybupropion or a prodrug of threohydroxybupropion are also disclosed.
Abstract: This disclosure relates to methods administering erythrohydroxybupropion or a prodrug thereof in conjunction with dextromethorphan to a human being.
Abstract: The present invention discloses novel agents and methods for diagnosis and treatment of melanoma. Also disclosed are related arrays, kits, and screening methods.
Abstract: The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.
Type:
Grant
Filed:
March 6, 2013
Date of Patent:
July 26, 2016
Assignees:
The Board of Trustees of the University of Illinois, Vanquish Oncology, Inc.
Inventors:
Paul J. Hergenrother, Rachel C. Botham, Timothy M. Fan, Mark J. Gilbert, Michael K. Handley, Howard S. Roth, Theodore M. Tarasow
Abstract: Methods of stimulating an increase in biomass by stimulating the growth, lifespan and/or reproduction of organisms such as fungi, algae, plants, and other aquatic organisms are provided by applying an effective amount of functionalized fullerenes. For example, polyhydroxy fullerenes are effective at low levels of promoting the increase in biomass.
Type:
Grant
Filed:
April 7, 2011
Date of Patent:
July 26, 2016
Assignee:
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
Inventors:
Jie Gao, Vijay Krishna, Wei Bai, Benjamin L. Koopman, Brij M. Moudgil, Paul Anthony Indeglia, Kevin Michael Folta, Angelina Tsenova Georgieva
Abstract: The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.
Abstract: Provided is a fat or oil composition, comprising the following components (A) and (B): (A) 0.4 to 6 mass % of a free type triterpene alcohol; and (B) 0.2 to 3 mass of a free type phytosterol containing 20 mass % or more of ?-sitosterol, in which a content mass ratio of the free type triterpene alcohol (A) to the free type phytosterol (B), [(A)/(B)], is 0.9 or more.
Abstract: Polymerization inhibitor compositions are provided. The polymerization inhibitor compositions may include at least one hydroxylamine of a nitroxide and at least one phenylenediamine. Methods of inhibiting the unwanted polymerization of monomers are also provided. The methods include adding the presently disclosed polymerization inhibitor compositions to a fluid containing the monomers. The monomers may be ethylenically unsaturated monomers, such as acrylic acid, methacrylic acid, acrylonitrile, methacrylonitrile, acrolein, methacrolein, acrylate, methacrylate, acrylamide, methacrylamide, vinyl acetate, butadiene, ethylene, propylene, and styrene.